Notch signaling in glioblastoma: A developmental drug target?

72Citations
Citations of this article
122Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Malignant gliomas are among the most devastating tumors for which conventional therapies have not significantly improved patient outcome. Despite advances in imaging, surgery, chemotherapy and radiotherapy, survival is still less than 2 years from diagnosis and more targeted therapies are urgently needed. Notch signaling is central to the normal and neoplastic development of the central nervous system, playing important roles in proliferation, differentiation, apoptosis and cancer stem cell regulation. Notch is also involved in the regulation response to hypoxia and angiogenesis, which are typical tumor and more specifically glioblastoma multiforme (GBM) features. Targeting Notch signaling is therefore a promising strategy for developing future therapies for the treatment of GBM. In this review we give an overview of the mechanisms of Notch signaling, its networking pathways in gliomas, and discuss its potential for designing novel therapeutic approaches. © 2010 Lino et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Lino, M. M., Merlo, A., & Boulay, J. L. (2010, November 15). Notch signaling in glioblastoma: A developmental drug target? BMC Medicine. https://doi.org/10.1186/1741-7015-8-72

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free